ArticleCancers2026
Spatial Dosimetric-Based Prediction of Long-Term Urinary Toxicity After Permanent Prostate Brachytherapy.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the correlation between spatial dose distribution and post-implant urinary toxicity, aiming to assist decision making in low-dose-rate (LDR) treatment planning, thereby improving patient outcomes.
methodsEighty-five prostate LDR patients with >12-month follow-up were included. Patient-reported urinary toxicity was collected prospectively using the International Prostate Symptom Score (IPSS) questionnaire, from before implant (baseline) to post-implant follow-up. Patients were then grouped into those whose symptom scores returned to ≤2 points above baseline by 12 months (no long-term toxicity) vs. those who did not (long-term toxicity). A total of 106 features were extracted for each patient, including principal components of dose-volume histograms (DVHs) from multiple prostate subzones, the whole prostate and urethra, along with baseline IPSS, implantation characteristics, and additional DVH indicators for the prostate and the urethra. A machine learning (ML) model incorporating backward feature selection algorithm was developed to predict long-term toxicity status, using a shuffle-and-split validation strategy for model evaluation during feature selection. A univariate statistical analysis was conducted on the model's selected features.
resultsOut of 85 patients, 41 (48%) had long-term urinary toxicity. Seven features were selected during model training, including baseline IPSS and six dosimetric features from several prostate subzones primarily located in the posterior prostate. The model achieved a high mean area under the receiver operating characteristic curve (AUC) of 0.81, with a balanced sensitivity and specificity of 0.78 by adjusting the probability threshold. In univariate analysis, only baseline IPSS and one selected dose feature were significantly correlated with long-term toxicity with AUC < 0.71.
conclusionsThe proposed ML model, integrating baseline IPSS and spatial dosimetric features, effectively predicts long-term urinary toxicity after prostate LDR. This approach offers a practical method for risk stratification, allowing clinicians to identify patients at elevated risk and prioritize them for targeted preventative measures and closer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.